Abstract
Prior asthma exacerbations have been associated with lung function decline and increased risk of future exacerbations. Dupilumab, a human monoclonal antibody, blocks IL-4/IL-13, key central drivers of type 2 inflammation. We investigated the relationship between prior exacerbations and lung function in patients with moderate-to-severe type 2 asthma (blood eosinophils ≥150cells/μL or FeNO ≥25ppb at parent study baseline [PSBL]) from QUEST (NCT02414854) who enrolled in TRAVERSE (NCT02134028).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
